Sphingosine-1-phosphate receptor 1 (S1P1) is one of five high affinity G protein-coupled S1P receptors which mediate a variety of effects including lymphocyte recirculation in the blood. Non-selective S1P receptor agonists, such as FTY720, produce clinical immunosuppression useful for preventing transplant rejection and treating autoimmune diseases. However, they also cause bradycardia by activating S1P3, the receptor responsible for regulation of heart rate. SEW2871 is a selective S1P1 receptor agonist in both human and mouse that is not active at the S1P2-5 receptors. SEW2871, therefore, suppresses the immune response by decreasing the number of lymphocytes circulating in blood without causing bradycardia.
SEW2871 was used to mimic the effects of sphingosine-1 phosphate in HUVECs to study the innate immunity rendered by long pentraxin 3.
5-[4-PHENYL-5-(TRIFLUOROMETHYL)-2-THIENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]-1,2,4-OXADIAZOLE is used as medicament for treating and/or preventing cardiovascular conditions in patients with Fabry disease.
ChEBI: 5-[4-phenyl-5-(trifluoromethyl)-2-thiophenyl]-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole is an oxadiazole and a ring assembly.
Novel, potent and selective sphingosine-1-phosphate 1 (S1P 1 ) receptor agonist. Activates S1P 1 receptor with an EC 50 of 13 nM, but does not activate S1P 2 , S1P 3 , S1P 4 or S1P 5 receptors at concentrations up to 10 μ M. Cell-permeable and active in vivo .
SEW2871 is a selective agonist of spingosine-1 phosphate receptor. It exacerbates reperfusion arrhythmias by significantly prolonging the duration of ventricular tachycardia and ventricular fibrillation. SEW2871 modulates inflammatory reactions by influencing lymphocyte homing and cell migration. By the inhibition of proinflammatory molecules, SEW2871 reduces acute renal failure due to ischemia.